{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:59:06Z","timestamp":1791230346341,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PS 09\/01261"],"award-info":[{"award-number":["PS 09\/01261"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006473","name":"Ministerio de Ciencia Tecnolog\u00c3\u00ada y Telecomunicaciones","doi-asserted-by":"publisher","award":["SAF2010\/17043"],"award-info":[{"award-number":["SAF2010\/17043"]}],"id":[{"id":"10.13039\/501100006473","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.jhep.2011.12.008","type":"journal-article","created":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T16:04:13Z","timestamp":1326470653000},"page":"1033-1039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["PPAR\u03b1 activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats"],"prefix":"10.1016","volume":"56","author":[{"given":"Aina","family":"Rodr\u00edguez-Vilarrupla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e0rbara","family":"Lavi\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Garc\u00eda-Calder\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Rosado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Roglans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Carles","family":"Garc\u00eda-Pag\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2011.12.008_b0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0168-8278(00)80422-5","article-title":"Complications of cirrhosis. I. Portal hypertension","volume":"32","author":"Bosch","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.008_b0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/jhep.2003.50004","article-title":"Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers","volume":"37","author":"Graupera","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.12.008_b0015","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0168-8278(03)00347-7","article-title":"Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers","volume":"39","author":"Graupera","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.008_b0020","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/jhep.2002.31432","article-title":"The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough","volume":"35","author":"Wiest","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.12.008_b0025","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2337\/diab.46.8.1319","article-title":"Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients","volume":"46","author":"Auboeuf","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2011.12.008_b0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00018-003-3216-3","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"61","author":"Mandard","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jhep.2011.12.008_b0035","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/35013000","article-title":"Roles of PPARs in health and disease","volume":"405","author":"Kersten","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2011.12.008_b0040","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.pharmthera.2009.03.003","article-title":"Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease","volume":"122","author":"Robinson","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhep.2011.12.008_b0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jhep.2011.12.008_b0050","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.HYP.0000083511.91817.B1","article-title":"Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension","volume":"42","author":"Iglarz","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jhep.2011.12.008_b0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bjp.0705414","article-title":"Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats","volume":"140","author":"Kanie","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jhep.2011.12.008_b0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2210-2-10","article-title":"Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation","volume":"2","author":"Tabernero","year":"2002","journal-title":"BMC Pharmacol"},{"key":"10.1016\/j.jhep.2011.12.008_b0065","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1089\/ars.2008.2280","article-title":"PPARs and the cardiovascular system","volume":"11","author":"Hamblin","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.jhep.2011.12.008_b0070","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.bbrc.2006.01.052","article-title":"Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC","volume":"341","author":"Murakami","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2011.12.008_b0075","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.lfs.2008.02.002","article-title":"PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation","volume":"82","author":"Okayasu","year":"2008","journal-title":"Life Sci"},{"key":"10.1016\/j.jhep.2011.12.008_b0080","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/01.ATV.0000125706.86492.69","article-title":"Regulation of endothelial nitric oxide synthase by PPAR agonists: molecular and clinical perspectives","volume":"24","author":"Watts","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhep.2011.12.008_b0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.atherosclerosis.2006.08.041","article-title":"Fenofibrate improves age-related endothelial dysfunction in rat resistance arteries","volume":"193","author":"\u00c1lvarez de Sotomayor","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jhep.2011.12.008_b0090","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2004.09.110","article-title":"PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats","volume":"324","author":"Toyama","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2011.12.008_b0095","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2010.07.034","article-title":"Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"54","author":"Garcia-Caldero","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.008_b0100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.yjmcc.2006.05.013","article-title":"Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors","volume":"41","author":"Ichihara","year":"2006","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jhep.2011.12.008_b0105","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1476-5381.1994.tb13109.x","article-title":"Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates","volume":"112","author":"Alegret","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jhep.2011.12.008_b0110","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.exger.2005.05.006","article-title":"Different response of senescent female Sprague-Dawley rats to gemfibrozil and rosiglitazone administration","volume":"40","author":"Sanguino","year":"2005","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.jhep.2011.12.008_b0115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0168-8278(05)81564-8","article-title":"Simvastatin improves sinusoidal endothelial dysfunction in CCl4 cirrhotic rats","volume":"42","author":"Abraldes","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.008_b0120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bcp.2003.08.034","article-title":"Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARalpha","volume":"67","author":"Sanguino","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2011.12.008_b0125","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/gut.2008.149880","article-title":"Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension","volume":"58","author":"Lavina","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2011.12.008_b0130","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/hep.22166","article-title":"Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability","volume":"47","author":"Gracia-Sancho","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.12.008_b0135","first-page":"944","article-title":"Assessment of a method of isolation, purification, and cultivation of rat liver sinusoidal endothelial cells","volume":"70","author":"Braet","year":"1994","journal-title":"Lab Invest"},{"key":"10.1016\/j.jhep.2011.12.008_b0140","doi-asserted-by":"crossref","first-page":"G757","DOI":"10.1152\/ajpgi.00017.2004","article-title":"Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation","volume":"287","author":"DeLeve","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2011.12.008_b0145","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","article-title":"Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl(4) cirrhotic rats","volume":"46","author":"Abraldes","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.008_b0150","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jhep.2007.03.014","article-title":"Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers","volume":"47","author":"Gracia-Sancho","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.008_b0155","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.12.008_b0160","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jhep.2007.02.006","article-title":"Vascular endothelial dysfunction in cirrhosis","volume":"46","author":"Iwakiri","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.008_b0165","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrendo.2010.89","article-title":"PPARalpha: an emerging therapeutic target in diabetic microvascular damage","volume":"6","author":"Hiukka","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jhep.2011.12.008_b0170","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2011.12.008_b0175","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/01.HYP.0000187900.36455.4c","article-title":"Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators","volume":"46","author":"Han","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.jhep.2011.12.008_b0180","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.jhep.2008.01.021","article-title":"The management of portal hypertension: rational basis, available treatments and future options","volume":"48","author":"Bosch","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.008_b0185","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jhep.2005.07.036","article-title":"Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis","volume":"44","author":"Nagula","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.008_b0190","doi-asserted-by":"crossref","unstructured":"Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond) 2002;103:284S\u2013288S.","DOI":"10.1042\/CS103S284S"},{"key":"10.1016\/j.jhep.2011.12.008_b0195","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2008.04.014","article-title":"Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats","volume":"49","author":"Matei","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.008_b0200","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0016-5085(03)00909-0","article-title":"Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats","volume":"125","author":"Morales-Ruiz","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2011.12.008_b0205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CRD.0b013e31816b43d3","article-title":"Fibrate therapy: an update","volume":"16","author":"Remick","year":"2008","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.jhep.2011.12.008_b0210","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fernandez-Miranda","year":"2008","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2011.12.008_b0215","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:33:33Z","timestamp":1759174413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827812000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0168827812000463"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2011.12.008","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPAR\u03b1 activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2011.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}